Quarterly Results, Collaborations and Product Launches - Research Report on Onyx Pharmaceuticals, Express Scripts, NPS

 Quarterly Results, Collaborations and Product Launches - Research Report on
      Onyx Pharmaceuticals, Express Scripts, NPS Pharmaceuticals, Salix
                  Pharmaceuticals, and MannKind Corporation

PR Newswire

LONDON, August 14, 2013

LONDON, August 14, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Investors' Reports announced new research reports highlighting Onyx
Pharmaceuticals, Inc. (NASDAQ: ONXX), Express Scripts Holding Company (NASDAQ:
ESRX), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), Salix Pharmaceuticals, Ltd.
(NASDAQ: SLXP), and MannKind Corporation (NASDAQ: MNKD). Today's readers may
access these reports free of charge - including full price targets, industry
analysis and analyst ratings - via the links below.

Onyx Pharmaceuticals, Inc. Research Report

On August 8, 2013, Onyx Pharmaceuticals, Inc. (Onyx Pharmaceuticals) announced
that it is collaborating with Idis Limited to initiate a Managed Access
Program for carfilzomib in some European countries for the treatment of
patients with multiple myeloma, who have received at least two prior
therapies, including bortezomib and an immunomodulatory agent, and have
demonstrated disease progression on or within 60 days of the completion of the
last therapy. Managed Access Programs enables biopharmaceutical companies to
allow eligible patients ethical access to medicines for unmet medical needs.
Pablo J. Cagnoni, M.D., Executive Vice President, Global Research &
Development and Technical Operations at Onyx Pharmaceuticals, said, "Idis is
the recognized leader in Managed Access Programs, making them an ideal partner
to oversee this important initiative on behalf of Onyx." The Full Research
Report on Onyx Pharmaceuticals, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.investorsreports.com/report/2013-08-12/ONXX]

Express Scripts Holding Company Research Report

On August 1, 2013, Express Scripts Holding Company (Express Scripts) and
Walgreens (Walgreens) announced the launch of Smart90 Walgreens, a new program
for Express Scripts clients interested in 90-day prescription drug programs
that result in lower costs and improve health outcomes for patients with
chronic disease who require long-term treatment. According to Express Scripts,
with Smart90 Walgreens, plan sponsors that wish to include Walgreens as part
of the Smart90 program for their pharmacy benefit will provide their members
who have chronic conditions the choice to receive 90-day supplies of
maintenance medications through home delivery from Express Scripts or directly
at a Walgreens retail pharmacy for the same copayment. Glen Stettin, M.D.,
Senior Vice President of Research and New Solutions at Express Scripts, said,
"Members will be able to continue to receive the safety, convenience, cost
savings and care offered from Express Scripts home delivery pharmacies." The
Full Research Report on Express Scripts Holding Company - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.investorsreports.com/report/2013-08-12/ESRX]

NPS Pharmaceuticals, Inc. Research Report

On August 8, 2013, NPS Pharmaceuticals, Inc. (NPS Pharmaceuticals) reported
its Q2 2013 financial results. The Company's total revenues declined 31.8% YoY
to $36.5 million during the quarter. Net loss was $12.4 million, or $0.13 per
diluted share, in Q2 2013, compared to net income of $7.4 million, or $0.08
per diluted share, in Q2 2012. Net product sales for Gattex, launched in Q1
2013 totaled $4.8 million in Q2 2013. Commenting on the results, Francois
Nader, MD, President and Chief Executive Officer of NPS Pharmaceuticals, said,
"Our commitment to flawless execution has yielded solid second quarter results
including Gattex sales that exceeded our own expectations. We are particularly
gratified to have already brought this life-changing treatment to 141 Short
Bowel Syndrome patients and I am pleased to report that we are increasing our
guidance to 275 to 325 patients on therapy by the end of the year." The Full
Research Report on NPS Pharmaceuticals, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.investorsreports.com/report/2013-08-12/NPSP]

Salix Pharmaceuticals, Ltd. Research Report

On August 8, 2013, Salix Pharmaceuticals, Ltd. (Salix Pharmaceuticals)
reported its Q2 2013 financial results and other business updates.The
Company's net product revenue grew 30.1% YoY to $235.4 million for the
quarter. Net income was $21.0 million, or $0.32 per diluted share, in Q2 2013,
compared to net income of $20.1 million, or $0.32 per diluted share, in Q2
2012. Commenting on the results, Adam Derbyshire, Executive Vice President and
Chief Financial Officer, said, "During the quarter our XIFAXAN 550 mg
prescription business demonstrated impressive growth of 26% compared to the
second quarter of 2012. APRISO also demonstrated strong prescription
year-over-year growth of 45% for the second quarter of 2013 compared to the
second quarter of 2012. RELISTOR prescriptions increased 48% year-over-year
for the second quarter of 2013 compared to the second quarter of 2012." The
Full Research Report on Salix Pharmaceuticals, Ltd. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.investorsreports.com/report/2013-08-12/SLXP]

MannKind Corporation Research Report

On August 9, 2013, MannKind Corporation (MannKind) reported its Q2 2013
financial results. The Company's total operating expenses decreased 5.6% YoY
to $41.6 million during the quarter. Research and development (R&D) expenses
increased 1.6% YoY to $27.1 million in Q2 2013, primarily due to an increase
in non-cash stock compensation expense partially offset by a decrease in
clinical trial related expenses. Net loss applicable to common stockholders
was $46.1 million, or $0.16 per diluted share, in Q2 2013, compared to net
loss of $36.6 million, or $0.23 per diluted share, in Q2 2012. Cash and cash
equivalents were $28.5 million as of June 30, 2013, compared to $61.8 million
as of December 31, 2012, with $125.4 million remaining available for future
borrowings under the loan agreement with Mann Group through September 30,
2013. The Full Research Report on MannKind Corporation - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.investorsreports.com/report/2013-08-12/MNKD]

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    making mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Investors' Reports

Contact: CONTACT PERSON: Kristi Saunders, CONTACT PHONE: +1-315-982-6420
(North America)
 
Press spacebar to pause and continue. Press esc to stop.